Bio-Path Holdings Inc. (NASDAQ: BPTH)
$1.94
+0.0200 ( +1.04% ) 72.9K
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
Market Data
Open
$1.94
Previous close
$1.92
Volume
72.9K
Market cap
$3.97M
Day range
$1.89 - $2.01
52 week range
$1.59 - $30.00
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
10-q | Quarterly Reports | 49 | Nov 14, 2023 |
def | Proxies and info statements | 3 | Oct 27, 2023 |
8-k | 8K-related | 14 | Oct 24, 2023 |
8-k | 8K-related | 12 | Sep 15, 2023 |
8-k | 8K-related | 14 | Aug 15, 2023 |
10-q | Quarterly Reports | 44 | Aug 14, 2023 |
8-k | 8K-related | 19 | Aug 07, 2023 |
8-k | 8K-related | 14 | Aug 01, 2023 |
8-k | 8K-related | 14 | Jul 17, 2023 |